Payment overview · 2025
General Payments
$610.00
36 reported records · 10 companies
Healthcare provider profile · identity verified
Angela Eubanks
Allopathic & Osteopathic Physicians|Family Medicine · GRANVILLE, OH · NPI 1386681104
Verified facts
What the public records show
CMS Open Payments records show Angela Eubanks received $610.00 in general payments during 2025 across 36 reported records.
ABBVIE INC. accounted for 46.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Synthroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $285.76 | 46.9% | 18 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $90.02 | 14.8% | 5 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $75.69 | 12.4% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $40.46 | 6.6% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $34.51 | 5.7% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $28.48 | 4.7% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.06 | 2.3% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $13.85 | 2.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.60 | 2.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $13.57 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $610.00 | 36 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $149.51 | 9 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $136.25 | 9 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $126.91 | 7 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $90.02 | 5 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $75.69 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $72.02 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $40.46 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $34.51 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $28.48 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $28.48 | 2 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $28.48 | 2 | 2025 |
Source payment records
|
|||||
| ROTATEQ Normalized: rotateq |
Biological | Merck Sharp & Dohme LLC | $14.37 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | Merck Sharp & Dohme LLC | $14.37 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $14.11 | 1 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $14.11 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $14.06 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $13.85 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $13.60 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $13.57 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $11.30 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 69 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
69 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
116 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 476 | 126 |
| Levothyroxine Sodium | Levothyroxine Sodium | 475 | 119 |
| Atorvastatin Calcium | Atorvastatin Calcium | 358 | 107 |
| Metoprolol Succinate | Metoprolol Succinate | 263 | 75 |
| Losartan Potassium | Losartan Potassium | 259 | 71 |
| Pantoprazole Sodium | Pantoprazole Sodium | 259 | 77 |
| Lisinopril | Lisinopril | 240 | 65 |
| Omeprazole | Omeprazole | 240 | 67 |
| Pravastatin Sodium | Pravastatin Sodium | 238 | 63 |
| Gabapentin | Gabapentin | 224 | 75 |
| Hydrochlorothiazide | Hydrochlorothiazide | 211 | 70 |
| Famotidine | Famotidine | 200 | 62 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 195 | 63 |
| Montelukast Sodium | Montelukast Sodium | 180 | 56 |
| Potassium Chloride | Potassium Chloride | 162 | 50 |
| Trazodone Hcl | Trazodone Hcl | 140 | 38 |
| Metformin Hcl Er | Metformin Hcl | 138 | 46 |
| Simvastatin | Simvastatin | 135 | 37 |
| Buspirone Hcl | Buspirone Hcl | 129 | 38 |
| Metformin Hcl | Metformin Hcl | 126 | 38 |
| Furosemide | Furosemide | 125 | 47 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 123 | 61 |
| Eliquis | Apixaban | 116 | 24 |
| Valsartan | Valsartan | 109 | 31 |
| Jardiance | Empagliflozin | 108 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 96 | 30 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 96 | 25 |
| Tramadol Hcl | Tramadol Hcl | 91 | 15 |
| Glimepiride | Glimepiride | 88 | 24 |
| Sertraline Hcl | Sertraline Hcl | 82 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 81 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 80 | 36 |
| Prednisone | Prednisone | 76 | 42 |
| Warfarin Sodium | Warfarin Sodium | 74 | 17 |
| Januvia | Sitagliptin Phosphate | 73 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 72 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 70 | 21 |
| Ozempic | Semaglutide | 69 | 12 |
| Fenofibrate | Fenofibrate | 68 | 18 |
| Celecoxib | Celecoxib | 65 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 64 | 17 |
| Alendronate Sodium | Alendronate Sodium | 63 | 20 |
| Atenolol | Atenolol | 61 | 17 |
| Allopurinol | Allopurinol | 59 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 58 | 20 |
| Carvedilol | Carvedilol | 57 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 57 | 14 |
| Methylprednisolone | Methylprednisolone | 57 | 50 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 55 | 18 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 53 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 52 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 51 | 12 |
| Colestipol Hcl | Colestipol Hcl | 51 | 14 |
| Trulicity | Dulaglutide | 51 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 50 | 14 |
| Ezetimibe | Ezetimibe | 49 | 16 |
| Breo Ellipta | Fluticasone/Vilanterol | 47 | suppressed |
| Cephalexin | Cephalexin | 46 | 34 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 44 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 41 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 41 | 15 |
| Ramipril | Ramipril | 40 | 12 |
| Bupropion Xl | Bupropion Hcl | 39 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 38 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 36 | 14 |
| Synthroid | Levothyroxine Sodium | 36 | suppressed |
| Meloxicam | Meloxicam | 35 | 15 |
| Nystatin | Nystatin | 35 | 27 |
| Spironolactone | Spironolactone | 35 | 12 |
| Glipizide Er | Glipizide | 34 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 34 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 33 | 30 |
| Irbesartan | Irbesartan | 33 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 32 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Lorazepam | Lorazepam | 30 | suppressed |
| Memantine Hcl | Memantine Hcl | 30 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 29 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 29 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 29 | 17 |
| Topiramate | Topiramate | 29 | suppressed |
| Alprazolam | Alprazolam | 28 | suppressed |
| Diazepam | Diazepam | 28 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 28 | suppressed |
| Azithromycin | Azithromycin | 27 | 24 |
| Mirtazapine | Mirtazapine | 27 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 27 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 26 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 26 | 14 |
| Pregabalin | Pregabalin | 26 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 26 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 26 | suppressed |
| Amoxicillin | Amoxicillin | 25 | 23 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 25 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 25 | suppressed |
| Klor-Con M10 | Potassium Chloride | 24 | 13 |
| Baclofen | Baclofen | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 23 | suppressed |
| Verapamil Er | Verapamil Hcl | 23 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 22 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 16 |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 15 |
| Clonazepam | Clonazepam | 20 | suppressed |
| Fluconazole | Fluconazole | 20 | 17 |
| Gemfibrozil | Gemfibrozil | 20 | suppressed |
| Mupirocin | Mupirocin | 20 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | 12 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 16 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | 12 |
| Finasteride | Finasteride | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 12 | suppressed |
| Indapamide | Indapamide | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $610.00 · 36 records | ABBVIE INC. | Auvelity, CAPVAXIVE, ENFLONSIA, FARXIGA, FREESTYLE LIBRE 3, GARDASIL 9, M-M-R II, Ozempic, PAXLOVID, QULIPTA, REXULTI, ROTATEQ, Rybelsus, SYNTHROID, UBRELVY, VAXELIS, VAXNEUVANCE, VOQUEZNA, VRAYLAR, Veozah | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error